Bluebird Bio Inc. (NASDAQ:BLUE) traded up 5.2% during trading on Wednesday . The stock traded as high as $58.27 and last traded at $58.27, with a volume of 462,318 shares. The stock had previously closed at $55.41.

Several equities research analysts have recently commented on the company. Leerink Swann restated an “outperform” rating and issued a $67.00 price objective on shares of Bluebird Bio in a research note on Thursday. Maxim Group restated a “buy” rating and issued a $85.00 price objective (down from $105.00) on shares of Bluebird Bio in a research note on Thursday. Wedbush restated an “outperform” rating and issued a $117.00 price objective on shares of Bluebird Bio in a research note on Wednesday. Jefferies Group restated a “positive” rating and issued a $80.00 price objective on shares of Bluebird Bio in a research note on Thursday, July 14th. Finally, Vetr downgraded shares of Bluebird Bio from a “buy” rating to a “hold” rating and set a $44.44 target price for the company. in a report on Monday, July 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $94.84.

The firm’s market capitalization is $2.09 billion. The company’s 50-day moving average price is $47.17 and its 200 day moving average price is $45.82.

Bluebird Bio (NASDAQ:BLUE) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. The business had revenue of $1.55 million for the quarter, compared to the consensus estimate of $2.01 million. The company’s revenue was down 68.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.57) earnings per share. On average, analysts expect that Bluebird Bio Inc. will post ($5.91) earnings per share for the current year.

In other news, insider Eric Sullivan sold 2,807 shares of the company’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total value of $126,427.28. Following the completion of the transaction, the insider now owns 4,656 shares in the company, valued at approximately $209,706.24. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider David Davidson sold 1,000 shares of the company’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $38.73, for a total transaction of $38,730.00. Following the completion of the transaction, the insider now owns 10,600 shares of the company’s stock, valued at approximately $410,538. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently modified their holdings of BLUE. Rhumbline Advisers boosted its position in shares of Bluebird Bio by 6.0% in the fourth quarter. Rhumbline Advisers now owns 35,855 shares of the company’s stock valued at $2,303,000 after buying an additional 2,023 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Bluebird Bio by 6.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 74,831 shares of the company’s stock valued at $4,806,000 after buying an additional 4,454 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of Bluebird Bio by 157.2% in the fourth quarter. California Public Employees Retirement System now owns 94,400 shares of the company’s stock valued at $6,062,000 after buying an additional 57,700 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Bluebird Bio by 374.8% in the fourth quarter. Marshall Wace LLP now owns 168,427 shares of the company’s stock valued at $10,816,000 after buying an additional 132,956 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its position in shares of Bluebird Bio by 27.8% in the fourth quarter. New York State Common Retirement Fund now owns 171,022 shares of the company’s stock valued at $10,983,000 after buying an additional 37,178 shares during the last quarter.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.